Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses
Launched by UNIVERSITY OF REGENSBURG · Sep 27, 2019
Trial Information
Current as of June 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the effects of a treatment called Cytoreductive Surgery followed by HIPEC (Heated Intraperitoneal Chemotherapy) for patients with a condition known as peritoneal carcinomatosis, which is cancer spread to the lining of the abdomen. The researchers want to understand how well this treatment works over time in helping patients manage their condition.
To be eligible for this study, participants should be between 65 and 74 years old and have signs of peritoneal carcinomatosis. Unfortunately, younger individuals under 18 cannot take part. Those who join the trial can expect to undergo the surgery and chemotherapy, and their progress will be monitored over time to see how they respond to the treatment. This trial is currently recruiting participants, so if you or a loved one are interested, it may be a good opportunity to consider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • suspicious peritoneal carcinomatosis
- Exclusion Criteria:
- • \<18 years
About University Of Regensburg
The University of Regensburg is a prestigious academic institution located in Germany, renowned for its commitment to advancing medical research and education. With a strong emphasis on interdisciplinary collaboration, the university conducts innovative clinical trials aimed at improving patient outcomes and contributing to the global body of medical knowledge. The institution's research initiatives are supported by state-of-the-art facilities and a diverse team of experts across various fields, ensuring rigorous scientific methodologies and ethical standards. Through its clinical trial sponsorship, the University of Regensburg seeks to foster advancements in healthcare while promoting the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Regensburg, , Germany
Regensburg, Bavaria, Germany
Patients applied
Trial Officials
Matthias Hornung, MD
Study Director
Dept. of Surgery, University Hospital Regensburg
Jens M Werner, MD
Principal Investigator
Dept. of Surgery, University Hospital Regensburg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials